Cetirizine 10mg + Cetirizine 10 mg + Cetirizine 10 mg

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Allergy

Conditions

Allergy

Trial Timeline

Dec 11, 2018 → Feb 3, 2019

NCT ID

NCT03772158

About Cetirizine 10mg + Cetirizine 10 mg + Cetirizine 10 mg

Cetirizine 10mg + Cetirizine 10 mg + Cetirizine 10 mg is a phase 1 stage product being developed by Johnson & Johnson for Allergy. The current trial status is completed. This product is registered under clinical trial identifier NCT03772158. Target conditions include Allergy.

What happened to similar drugs?

4 of 14 similar drugs in Allergy were approved

Approved (4) Terminated (3) Active (7)

✅Placebo + XolairNovartisApproved

✅OmalizumabNovartisApproved

✅Omalizumab InjectionRocheApproved

✅Fexofenadine HCISanofiApproved

❌ligelizumab + PlaceboNovartisPhase 3

❌Ligelizumab 120 mg + Ligelizumab 240 mgNovartisPhase 3

🔄Omalizumab + Placebo for Omalizumab + Multi-Allergen Oral Immunotherapy + Placebo for Multi-Allergen Oral ImmunotherapyNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03772158	Phase 1	Completed	Dec 11, 2018	Feb 3, 2019	Allergy

Competing Products

20 competing products in Allergy

See all competitors

Product	Company	Stage	Hype Score
ASP0892 Intradermal + ASP0892 Intramuscular + Placebo Intradermal + Placebo Intramuscular	Astellas Pharma	Phase 1	29
ASP0892 + Placebo	Astellas Pharma	Phase 1	29
Cetirizine + Cetirizine	Johnson & Johnson	Phase 1	29
Acalabrutinib	AstraZeneca	Phase 2	35
Omalizumab	Novartis	Phase 1	29
ligelizumab + Placebo	Novartis	Phase 3	32
remibrutinib + placebo	Novartis	Phase 2	35
Placebo + Xolair	Novartis	Approved	39
QGE031 + Placebo	Novartis	Phase 2	27
Ligelizumab 120 mg + Ligelizumab 240 mg	Novartis	Phase 3	32
Omalizumab + Placebo for Omalizumab + Multi-Allergen Oral Immunotherapy + Placebo for Multi-Allergen Oral Immunotherapy	Novartis	Phase 3	40
QGE031 + Placebo	Novartis	Phase 1	29
Omalizumab	Novartis	Approved	43
Omalizumab Injection	Roche	Approved	50
Fluticasone + Fluticason	Roche	Pre-clinical	26
Dupilumab + Placebo matching dupilumab + AR101	Sanofi	Phase 2	35
Fexofenadine HCI	Sanofi	Approved	43
Dupilumab	Sanofi	Phase 2	35
Glucopyranosyl Lipid A (GLA) + Sublingual Immuno Therapy (SLIT) Peanut Extract (PE) + Placebo for GLA + Placebo for SLIT PE	Sanofi	Phase 1	29
Dupilumab	Regeneron Pharmaceuticals	Pre-clinical	26